Europe Alzheimer Drug Pipeline Analysis

61 views

Published on

“Europe Alzheimer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process.

For Report Sample Contact: rajesh@pnspharma.com

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
61
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Europe Alzheimer Drug Pipeline Analysis

  1. 1. Europe Alzheimer Drug Pipeline Analysis The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure on the social and health-care systems of the region. There is an urgent need for developing curative or disease-modifying therapies to offset the upcoming AD epidemic. “Europe Alzheimer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process. For Report Sample Contact: rajesh@pnspharma.com Following parameters for each drug profile in development phase are covered in “Europe Alzheimer Drug Pipeline Analysis” research report: • Drug Profile Overview • Alternate Names for Drug • Active Indication • Phase of Development • Mechanism of Action • Brand Name • Patent Information • Country for Clinical Trial • Owner / Originator/ Licensee/Collaborator • Administrative Route • Drug Class • ATC Codes
  2. 2. Europe Alzheimer Drug Pipeline by Clinical Phase: • Research: 19 • Preclinical: 49 • Clinical: 1 • Phase-I: 25 • Phase-I/II: 2 • Phase-II: 26 • Phase-II/III: 2 • Phase-III: 5 • Preregistration: 2 • Marketed: 10 • Unknown: 1 For Report Sample Contact: rajesh@pnspharma.com Each Drug Profile has Tables Representing Following Information: • Alternate Names • Originator & Owner • Collaborator • Technology Provider • Licensee • Highest Development Phase • Indications • Class • Mechanism of Action • ATC Code • Designated Brand Name

×